國家衛生研究院 NHRI:Item 3990099045/14507
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 906184      在线人数 : 779
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14507


    题名: Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
    作者: Su, YY;Lee, WH;Wang, JH;Wang, HW;Chen, TW;Chen, BB;Ho, HJ;Liu, TH;Chou, SC;Chen, BR;Liu, TW;Chen, LT;Wu, CY;Hsu, C
    贡献者: National Institute of Cancer Research
    摘要: Background: Gut microbiome may modulate the host immune system and correlate with antitumor efficacy of immune checkpoint inhibitor (ICI) therapy. This study explored whether gut microbiome may serve as a biomarker for ICI efficacy for HCC in a prospective study. Methods: Details of trial design were disclosed in ClinicalTrials.gov (NCT03510871). Patients with potentially resectable HCC received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks (N+I). Enrolled subjects were evaluated for surgery after 2 to 4 cycles of N+I. Bacterial DNA was extracted from stool samples, collected before the start of the first cycle, after 2 and 4 cycles of N+I, and at the end-of-treatment, for 16S rRNA sequencing. Quality-filtered reads were used to generate operational taxonomic units. The alpha-diversity comparison was carried out by Kruskal-Wallis test. Principal coordinate analysis was performed to analyze similarities between groups. Results: From February 2019 to January 2021, 66 stool samples were collected from 28 subjects (men/women 22/6, median age 62 years, HBsAg+/ anti-HCV+ 16/3, BCLC stage A/B/C 2/8/18, median tumor size 8.6 cm (range 7.5-11.5), median alpha-fetoprotein 81 ng/mL [range 8-1352]). There were 7 (25%) partial responses, 10 (35.7%) stable diseases, and 11 (39.3%) progressive diseases, and 15 subjects received curative surgery. As of February 2021 (median follow-up 13.4 months), 13 subjects remained progression-free. The diversities of gut microbiome were similar between subjects with or without progression, while the abundance of some bacteria was significantly higher in subjects without tumor progression. Conclusion: We observed a trend that the abundance of some bacteria was significantly higher in non-progressed subjects. This study will enroll a total of 40 subjects to clarify whether gut microbiome may serve as a predictive or prognostic biomarker in HCC patients treated with ICI therapy.
    日期: 2022-07
    關聯: Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
    Link to: http://dx.doi.org/10.1016/j.annonc.2022.05.110
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400210
    显示于类别:[蘇勇曄] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要
    [劉滄梧] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000834940400210.pdf96KbAdobe PDF126检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈